These findings suggest that PDE‐4 inhibitors, such as rolipram, may hold promise as potential therapeutic agents for the treatment of ureteral disorders attributable to increased intra‐ureteral pressure resulting from functional or mechanical obstruction of the ureter. The gene discussed is PDE4A; the disease is ureteral disorder.